
Bill Haney's latest startup scores deal from Sanofi, its newest Big Pharma partner, with $54M upfront
A heavily financed biotech looking to drug RNA with small molecules is adding yet another company to its Big Pharma shortlist.
Skyhawk Therapeutics, the biotech headed by serial entrepreneur and documentary filmmaker Bill Haney, announced an exclusive, back end-heavy collab deal Tuesday with Sanofi, which will primarily focus on yet-undisclosed targets in both immunology and oncology. Sanofi agreed to pay $54 million upfront, and if all the milestones are reached, that could add up to over $2 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.